An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
about
Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsLatent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccinesNanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway.The innovative evolution of cancer gene and cellular therapies.A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivoCombined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses.EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.Adenovirus as vehicle for anticancer genetic immunotherapy.Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections.The rationale for prophylactic cancer vaccines and need for a paradigm shift.DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.A versatile bifunctional dendritic cell targeting vaccine vectorVaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy.Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases.The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors.Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis.Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen.
P2860
Q24813328-E723B90C-0B3F-4F2E-906C-6E2DDF5B8FB3Q26776553-AA39B069-8D49-4D0D-928A-B74D74C8BF5AQ27497985-99A4DC62-546C-46A2-8791-EDE40EA9BEB0Q33509292-52D10DD3-9A3E-4D35-B312-97145807F881Q33713511-9AA2B7DB-DC0A-4757-B64A-3B4EA5ADF6A4Q34325544-3233315C-7D28-4CC5-829E-9B7822B9236BQ35005484-16A545FF-97CE-4445-9244-C4E3D2BC2E9EQ35082617-3095E2D9-5C57-4835-8C6B-A390F5ABE58FQ35096745-5459CBC0-3C0C-4A79-A103-E65452ABC858Q36288930-3BC7D09E-73E4-48B7-84FC-AA7376B4C578Q36349567-5EF121C6-0CC6-4B81-9665-7326138C5D28Q36423899-E3142058-3852-4125-9283-581BC659A446Q37010987-90A5ADDA-41C7-43C3-A6DE-C455693F52A5Q37183994-9BD3D3FB-479E-43DE-864E-B5ED63459A55Q37547365-35746A1A-0E5E-49BF-A44D-B9A21B0E979DQ37793233-93E242F8-E42E-49E8-B87F-99CBB00933B2Q37820820-2C4CD566-7AC0-452C-87A2-3EBA7CF58675Q37989571-6637349E-8B72-4A4F-AD48-B3CDC34C4045Q38067267-0D44E85F-5A20-4877-8811-8D5971FDA497Q38206518-0EC2F096-A1D7-4E7B-8A46-0F1424B8CD6CQ38992973-9329E723-6ABA-4841-84E7-B91053C76073Q39817819-DDEEEE15-9F84-4538-B21D-69C33D613646Q45880890-3AFBCFDF-3FDF-4D68-BCB0-B27A4DC7DB4FQ50768820-4A65C0E9-8DCA-461C-AB74-A35DBCF6CB73
P2860
An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
An adenoviral vector cancer va ...... on protein to dendritic cells.
@ast
An adenoviral vector cancer va ...... on protein to dendritic cells.
@en
An adenoviral vector cancer va ...... on protein to dendritic cells.
@nl
type
label
An adenoviral vector cancer va ...... on protein to dendritic cells.
@ast
An adenoviral vector cancer va ...... on protein to dendritic cells.
@en
An adenoviral vector cancer va ...... on protein to dendritic cells.
@nl
prefLabel
An adenoviral vector cancer va ...... on protein to dendritic cells.
@ast
An adenoviral vector cancer va ...... on protein to dendritic cells.
@en
An adenoviral vector cancer va ...... on protein to dendritic cells.
@nl
P2093
P2860
P356
P1476
An adenoviral vector cancer va ...... on protein to dendritic cells.
@en
P2093
Albert B Deisseroth
Daniel Zelterman
Hakan Akbulut
Lixin Zhang
Phyllis-Jean Linton
Yucheng Tang
P2860
P304
15101-15106
P356
10.1073/PNAS.2135379100
P407
P577
2003-11-25T00:00:00Z